Advertisements

Angiofilina

Quick links to important sections

Angiofilina

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Angiofilina

Quick Facts

Property Description
Active Ingredient Amlodipine (besylate salt)
Form Oral Tablet (solid form)
Pharmacological Class Calcium Channel Blocker (Dihydropyridine)
General Purpose Antihypertensive and Antianginal Agent
Origin Synthetic Small Molecule

What Type of Medicine is Angiofilina? (Identity and Classification)

Angiofilina is a prescription medication containing the active ingredient Amlodipine, a synthetic compound that is clinically recognized for its long-standing efficacy in cardiovascular care. Amlodipine is officially classified as a Calcium Channel Blocker (CCB), placing it among the essential agents used to regulate vascular function. Specifically, Amlodipine belongs to the dihydropyridine subclass, which is generally known for its pronounced selectivity toward vascular smooth muscle cells. As a single-ingredient product, Angiofilina is supplied in a tablet form for straightforward oral administration, designed to provide a consistent, long-acting therapeutic effect.


Angiofilina's Role in Vascular Management (General Purpose)

The primary therapeutic purpose of Angiofilina is to function as an antihypertensive and an antianginal agent by achieving widespread vasodilation. This action reduces peripheral vascular resistance, a mechanical benefit that lowers the physical strain on the heart as it attempts to circulate blood throughout the body. Research confirms the reliable clinical utility of Amlodipine as a highly effective agent for the long-term management of arterial pressure. By facilitating the widening of both the peripheral arteries and the coronary arteries, the medication allows more oxygenated blood to reach the myocardium (heart muscle). This general mechanism—reducing cardiac workload and improving coronary blood flow—is the basis of its therapeutic value in vascular management.

Advertisements

What side effects are possible with Angiofilina?

Possible Side Effects and Safety Information

The safety profile of Angiofilina (Amlodipine) is documented by regulatory agencies and classified according to the frequency of reported adverse reactions.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped based on the standard regulatory frequency framework, which is primarily categorized by the System-Organ Class (SOC) they affect. The most frequently observed adverse reaction is oedema (swelling, typically of the ankles), which is officially classified as Very Common (ge 1 in 10 patients) and noted as being dose-related in regulatory documents.

Classification Examples of Reactions
Common Headache, dizziness, somnolence, palpitations, flushing, abdominal pain, nausea, fatigue.
Uncommon Insomnia, mood changes, tremor, hypotension, dyspepsia, rash, muscle cramps, increased urinary frequency.
Very Rare Myocardial infarction, arrhythmia, pancreatitis, hepatitis, jaundice, Stevens-Johnson syndrome (SJS).

Serious and Contextual Safety Notes

Regulatory documents list certain rare events as potentially serious, including severe dermatologic reactions like SJS and Toxic Epidermal Necrolysis (TEN), as well as cardiovascular events such as myocardial infarction and specific arrhythmias.

Adverse reactions such as headache and flushing are commonly observed at the start of treatment. Safety information also notes that clearance of Amlodipine is often decreased in older adults and in patients with hepatic impairment, which can lead to increased systemic exposure. The medication is contraindicated in patients with severe hypotension and cardiogenic shock.

Advertisements

Overdose and Emergency Response

Overdose involving Angiofilina (Amlodipine) is primarily characterized by the physiological effects of excessive peripheral vasodilation leading to marked hypotension (severely low blood pressure). A reflex tachycardia may also present as a documented clinical manifestation. These effects define a severe presentation requiring urgent action.

Immediate medical help is required in cases of massive overdose. Regulatory guidance strictly mandates the initiation of active cardiac and respiratory monitoring for any suspected massive ingestion. Frequent blood pressure measurements are an essential component of the required medical observation.

The management of Angiofilina overdose is symptomatic and supportive, as no specific antidote is known. Due to the drug’s high protein binding, standard procedures like hemodialysis are not expected to be of benefit. Official procedures described for addressing marked hypotension include the elevation of the extremities and judicious administration of fluids to support cardiovascular function. If hypotension remains unresponsive, the administration of vasopressors, such as phenylephrine, may be considered. Additionally, intravenous calcium gluconate may be utilized to help reverse the effects of the calcium entry blockade.

Advertisements

Therapeutic Uses of Angiofilina

What Angiofilina Treats: Main Uses and Benefits

The therapeutic uses for Angiofilina (Amlodipine) are relevant in the long-term management of cardiovascular conditions, including chronic hypertension and multiple forms of angina. Angiofilina is indicated for the treatment of hypertension and Coronary Artery Disease (CAD), including chronic stable angina and vasospastic (Prinzmetal’s or Variant) angina.


Long-Term Management of High Blood Pressure

Angiofilina is generally used for the sustained, daily control of chronic hypertension (high blood pressure) in adults. The intended therapeutic role is to support the sustained control of arterial pressure, which supports a reduction of the long-term physical strain on the cardiovascular system. It contributes to improved functional stability in scenarios where patients experience symptoms related to systemic imbalance.


Symptomatic Relief for Chronic Angina

The medication is commonly used to help with symptom clusters that may become intense or disruptive, such as those associated with chronic stable and vasospastic angina. It is commonly used to help manage the frequency of anginal episodes and related discomfort. By easing the impact of symptoms that create noticeable functional strain, Angiofilina supports patients during episodes of heightened discomfort.


Quick Fact

Quick Fact: Relevant for Managing Elevated Blood Pressure and Anginal Chest Discomfort

Regulatory References

  1. NIH DailyMed amlodipine besylate tablet
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Angiofilina?

Eligibility for Angiofilina (Amlodipine) is strictly defined by official regulatory documentation and is based on a patient's medical status and age, not on therapeutic claims.

Absolute Non-Eligibility (Contraindications)

Classification Who Must NOT Use Angiofilina
Hypersensitivity Patients with a known allergy to amlodipine or other dihydropyridine derivatives.
Hemodynamic Status Individuals experiencing severe hypotension, shock (including cardiogenic shock), or outflow tract obstruction (e.g., severe aortic stenosis).

Age and Condition-Based Restrictions

Population Group Eligibility Status
Adults Eligible for all labeled uses.
Children 6–17 years Eligible for the treatment of hypertension only. Safety is not established for children under 6 years of age.
Older Adults Use requires caution, and treatment should be initiated at the low end of the dose range.
Hepatic Impairment Use is restricted; patients with severe impairment require caution and slow titration due to decreased drug clearance.
Pregnancy Safety has not been established in humans; use is restricted to when the benefit clearly outweighs the risk.
Lactation Official labeling advises discontinuing nursing while taking the medicine.

Angiofilina eligibility is not granted in the presence of these specific conditions, as documented in official prescribing information.

Advertisements

What should I know about interactions with other medicines?

Angiofilina Interactions with Other Medicines and Products

The interaction profile of Angiofilina (Amlodipine) is documented by regulatory agencies and is primarily driven by its metabolism through the CYP3A4 enzyme system and its influence on the systemic exposure of other drugs. This section details officially recognized interactions.

Contraindicated and Restricted Combinations

Classification Interacting Substance Context/Restriction
Contraindicated Dantrolene (intravenous) Risk of severe hyperkalemia; co-administration is not recommended.
Contraindicated Aliskiren-containing products Prohibited in patients with Diabetes Mellitus or Renal Impairment (GFR <60 mL/min/1.73 m^2).
Dose-Limited Simvastatin Simvastatin dose must be limited to 20 mg daily due to increased systemic exposure.

Exposure and Pharmacodynamic Effects

  • Increased Angiofilina Exposure: Co-administration with strong and moderate CYP3A4 inhibitors (e.g., Ketoconazole, Diltiazem, Clarithromycin) significantly increases Amlodipine plasma concentrations, which necessitates clinical monitoring.
  • Increased Exposure of Other Drugs: Amlodipine may increase the systemic levels of immunosuppressants such as Cyclosporine and Tacrolimus, requiring frequent therapeutic drug monitoring.
  • Additive Effects: Concomitant use with other antihypertensive agents or Sildenafil may result in an additive hypotensive effect.

Food and Population-Specific Notes

Consumption of Grapefruit or Grapefruit Juice is not recommended as it may increase Amlodipine's bioavailability. The interaction risk with CYP3A4 inhibitors is heightened in patients with hepatic impairment due to the drug's prolonged clearance.

Advertisements

Mechanism of Action

Molecular Blockade of L-Type Calcium Channels

Angiofilina's mechanism begins with the selective inhibition of the Voltage-Dependent L-type Calcium Channel ( Ca V1.2) found primarily in vascular smooth muscle cells. The active ingredient, Amlodipine, binds to these channels to impede the influx of extracellular calcium ions ( Ca^2+), which are essential for cellular contraction. This targeted block initiates the signaling cascade that alters vascular tone.


Cascade to Vasodilation and Afterload Reduction

The molecular blockade prevents the full activation of the Calcium-Calmodulin-MLCK pathway, resulting in the relaxation of arterial smooth muscle (vasodilation). This widening of the systemic arterioles causes a physiological reduction of Total Peripheral Resistance (TPR) (afterload) on the ventricle. This core mechanism also extends to the coronary arteries, promoting coronary vasodilation.


Mechanism-Dependent Onset and Constraint

Amlodipine's slow association and dissociation kinetics at the channel result in a gradual onset of effect. A key mechanistic constraint is its high vasoselectivity, meaning it preferentially dilates the arteries more than the veins, which influences the distribution of hydrostatic pressure in the periphery.

Advertisements

Dosage and Administration Information

How to Use Angiofilina

Angiofilina (Amlodipine) is administered as an oral tablet and is intended for consistent, once-daily use as part of a long-term treatment plan. The medication may be taken with or without food, as its absorption is not clinically altered by meals.


Standard Dosing Regimen

The standard adult treatment typically begins with an initial dose of 5 mg taken once per day. The maintenance range generally falls between 5 mg and 10 mg once daily, which is the maximum recommended dose for adults for all approved uses.


Dose Adjustment and Special Populations

Any adjustments to the dose must be executed slowly to allow for a full assessment of the medication's effect. A waiting period of at least 7 to 14 days is typically observed between dose increases. For specific patient groups, the starting dose is lower than the standard regimen:

  • Older Adults and Patients with Hepatic Impairment: Treatment should begin with a reduced initial dose of 2.5 mg once daily. Slow titration is necessary due to reduced drug clearance in patients with impaired liver function.
  • Pediatric Patients (6-17 years): The initial antihypertensive dose is 2.5 mg once daily, with a maximum dose of 5 mg once daily.

For patients with renal impairment, dose adjustments are typically not required as the degree of kidney function does not significantly alter the drug's plasma concentration.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Angiofilina

Evidence for use in Studies in High Blood Pressure

Research on Angiofilina was studied for its profile within the evidence base for high blood pressure. These studies included large-scale Randomized Controlled Trials (RCTs) that compared the medicine against other established treatments or a placebo (inactive substance). The research examined outcomes related to systemic or functional imbalance, primarily monitoring changes in blood pressure readings over time. Long-term research showed patterns related to the occurrence of serious events, such as stroke and heart attack, in comparison to a placebo or certain other comparator medications.

What remains uncertain is the data for long-term observations of Angiofilina when studied as a single agent (monotherapy), because many of the largest trials examined it as part of a combination regimen with other medications. This means the specific long-term outcomes for monotherapy are not fully established.


Evidence for use in Studies in Chronic Angina and Coronary Artery Disease

The evidence base explores Angiofilina in individuals with chronic angina (chest discomfort) and related conditions characterized by fluctuating or episodic manifestations. This research was structured to examine outcomes related to physical discomfort and daily functioning or activity level. Studies monitored changes in patient experience, including how often patients experienced anginal episodes and how frequently they needed to use rescue medication, such as nitroglycerin.

The findings describe patterns observed related to changes in the recorded frequency of anginal episodes. Some trials also reported how symptoms evolved in the observed populations, with measured outcomes related to functional capacity, such as the duration patients could sustain exercise.


Research in Specific Patient Groups

Research has been studied for Angiofilina across a range of populations, including large numbers of older adults in the hypertension trials. Research also explores Angiofilina in pediatric patients (children ages 6 through 17) with high blood pressure. However, the available data for this age group is limited to specific, lower doses, and results apply only to the populations studied. Data for other groups, such as pregnant or breastfeeding populations, remain insufficient.


Understanding Research Gaps and Uncertainty

Some trials focused on measuring the progression of underlying coronary vessel narrowing did not report findings that suggest a structural change to the vessels themselves. Additionally, the evidence for certain severe, complex, or low-incidence conditions is limited and often based on small study sizes or subgroup findings that are uncertain. Research provides context but not individual predictions.

Key Studies & References Amlodipine Besylate Tablet - DailyMed Label (NIH/NLM)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Angiofilina (FAQ)


Q: How quickly does Angiofilina start working after taking it?

A: Regulatory information indicates that Angiofilina starts to decrease blood pressure within 4 to 8 hours after a single dose. It may take 7 to 10 days of consistent, once-daily use for the drug's levels in the body to reach steady-state concentration, which is associated with achieving its full blood pressure-lowering profile.


Q: Can Angiofilina make me feel dizzy or sleepy?

A: Official documents list dizziness and somnolence (drowsiness) as Common side effects of this medicine. Regulatory documents indicate that adverse reactions such as headache and flushing are commonly observed at the start of treatment, and this pattern may apply to dizziness or drowsiness as well.


Q: Does Angiofilina have any severe side effects I should know about?

A: Official safety information lists certain rare and very rare events as potentially serious. These include severe skin reactions, such as Stevens-Johnson syndrome, and cardiovascular events, such as myocardial infarction (heart attack) or certain arrhythmias (irregular heartbeats).


Q: I'm on blood thinners. Can I still take Angiofilina?

A: Regulatory documents describe that Angiofilina may increase the blood levels of certain factor Xa inhibitors, which are a type of blood thinner, and this could lead to an increased risk of bleeding. The concurrent use of these medicines is often managed with clinical monitoring to manage potential risk, as described in regulatory documents.


Q: Are there any foods or drinks I should avoid while using Angiofilina?

A: According to official regulatory safety notes, the consumption of grapefruit or grapefruit juice is not recommended. This is because grapefruit may increase the amount of the medication absorbed by the body.


Q: What happens if I miss a dose of Angiofilina?

A: Official patient information generally advises taking the missed dose as soon as it is remembered unless it is close to the time for the next scheduled dose. If that is the case, the missed dose should be skipped and the regular schedule resumed. Official sources do not advise taking a double dose to make up for a missed one.


Q: Can Angiofilina affect my ability to drive or operate machinery?

A: Official documents advise that the ability to drive or use machinery may be impaired if the patient experiences side effects such as dizziness, somnolence (drowsiness), or fatigue. Caution is generally recommended when performing activities that require alertness, especially at the start of treatment.


Q: What should I do if the side effects of Angiofilina bother me?

A: Official patient information describes that concerning side effects should be brought to the attention of a healthcare provider or pharmacist. The regulatory label also notes specific severe reactions that warrant immediate medical attention.


Q: What does the official research say about the effectiveness of Angiofilina?

A: Official research, primarily Randomized Controlled Trials, has examined outcomes related to systemic imbalance. These studies found patterns related to a reduction in serious events such as stroke and heart attack compared to placebo or certain other comparator medications.


Q: Is it normal to feel a bit nauseous when first starting Angiofilina?

A: Official documents list nausea as a Common side effect. Adverse reactions such as headache and flushing are also commonly observed at the start of treatment, as the body adjusts to the medicine.


Q: Does Angiofilina interact with herbal supplements like St. John's Wort?

A: Regulatory information indicates that St. John's Wort may reduce the blood levels and effects of Angiofilina. The management of concurrent use often involves careful monitoring by a healthcare professional.


Q: Is Angiofilina safe to take if I have liver problems?

A: Regulatory documents state that use is restricted in patients with severe hepatic (liver) impairment. Regulatory documents indicate that for specific populations, such as those with hepatic (liver) impairment, treatment typically begins with a reduced initial dose due to decreased drug clearance.


Q: Can I take Angiofilina if I am pregnant or planning to be?

A: Official labeling states that safety has not been established in pregnant humans. The decision for use is reserved for situations where a healthcare professional determines that the expected benefit is greater than the potential risk, as safety has not been established in pregnant humans. Regarding breastfeeding, official labeling advises discontinuing nursing while taking the medicine.


Q: What happens if I stop taking Angiofilina suddenly?

A: Official documentation notes that upon discontinuing the medication, blood pressure levels slowly return to baseline over 7 to 10 days. There is typically no evidence of a sudden, unwanted surge in blood pressure, known as a 'rebound effect'.


Q: Does Angiofilina cause weight gain or weight loss?

A: Official documents list weight gain as a less common (Uncommon) adverse reaction in the safety profile of this medicine.


Q: How long does the effect of one dose of Angiofilina typically last?

A: The long-acting nature of the active ingredient is described by its slow elimination half-life of 40 to 60 hours. This mechanism is the reason a single dose is designed to maintain its blood pressure-lowering effect for over 24 hours.


Q: Why is Angiofilina sometimes prescribed for conditions not listed in its main uses?

A: Official regulatory bodies approve the medication only for its stated indications (main uses). Prescribing for other conditions not listed on the official label is known as 'off-label' use, which is outside the scope of the authoritative content provided by the regulatory agencies.


Q: Is there a generic version of Angiofilina available?

A: Yes, the active ingredient in Angiofilina, Amlodipine, is available from various manufacturers as a generic tablet. These are listed in regulatory product registries.


Q: Do I need regular blood tests while I am taking Angiofilina?

A: Regulatory information for Angiofilina alone typically does not list routine blood tests as a mandatory requirement for patient monitoring, although blood tests may be necessary if it is used in combination with other specific medications or for certain underlying health conditions.


Q: Are there any long-term effects of taking Angiofilina for many years?

A: The safety profile, including very rare events, is monitored during long-term use. Long-term research has shown patterns related to serious events. However, the evidence for very long-term outcomes (many years) of the drug as a single agent is not fully established, with some sources noting this as a limitation of the available clinical data.


Q: Does Angiofilina make people feel anxious or nervous?

A: Official documents list anxiety as an uncommon (0.1% to 1%) side effect and nervousness as a reaction with a frequency that has not been reported.


Q: Is Angiofilina an over-the-counter medicine?

A: No, Angiofilina is classified as a prescription medicine (POM—Prescription Only Medicine) and cannot be purchased over-the-counter.


Q: Is Angiofilina safe for people who have diabetes?

A: Regulatory documents do not list diabetes mellitus as a contraindication for Angiofilina used alone. However, the co-administration with certain other medicines (e.g., Aliskiren-containing products) is restricted in patients who have diabetes.


Q: Are there specific symptoms that mean Angiofilina is not working?

A: Because high blood pressure often has no symptoms, a patient may not feel differently even when the medicine is working. The primary indicator of its effectiveness is a change in blood pressure readings, as monitored by a healthcare professional, and it may not be associated with a change in physical symptoms.


Q: Does Angiofilina contain any ingredients that cause problems for people with lactose intolerance?

A: Some tablet formulations of the active ingredient (Amlodipine) may contain an excipient called lactose. Individuals with lactose intolerance should consult the specific patient information leaflet for their product's full list of ingredients.


Q: Does Angiofilina have a known risk of dependence?

A: The official labeling does not classify the active ingredient in Angiofilina as a controlled substance and does not list dependence or abuse as a general risk associated with the medication.


Q: Can Angiofilina cause problems with sleep?

A: Official documents list insomnia (difficulty sleeping) as an Uncommon side effect, occurring in 0.1% to 1% of patients.

Advertisements

How should Angiofilina be stored and disposed of?

Official Storage and Disposal Requirements

Angiofilina (Amlodipine oral tablets) must be stored and discarded according to strict regulatory guidelines to ensure product integrity and public safety. These instructions are based on official government labeling and apply to the final product form.


️ Storage and Handling

Requirement Official Rule
Temperature Store at room temperature, typically 20 C to 25 C.
Protection Keep away from heat, moisture, and light. Do not store in the bathroom.
Handling Keep from freezing. Store in the original container, tightly closed.

️ Child Safety and Disposal

Official labeling mandates that Angiofilina must be stored out of the sight and reach of children, with safety caps locked securely. Unused or expired medication should be disposed of according to local regulations; consult a pharmacist or healthcare provider for options like drug take-back programs. Due to the environmental classification of the active ingredient, the product must not be flushed down the toilet or released into the sanitary sewer system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angiofilina found in:

A-Z Index: